Mon, Jan 26, 2015, 10:27 AM EST - U.S. Markets close in 5 hrs 33 mins


% | $
Quotes you view appear here for quick access.

Arena Pharmaceuticals, Inc. Message Board

streetmartianx 5 posts  |  Last Activity: Jan 22, 2015 2:37 PM Member since: Jun 2, 2005
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • its time for insiders to step up and show confidence in this company. i have been a shareholder for many years and have dismissed the lack of insider purchasing. however, it should be a growing concern for longs. the recent spate of positives, if realistic, should spur insiders to buy. if they continue to collect share under option plans, sell them and replenish, their lack of commitment is patent.

    management continues to spend without constraint. this must be raised at the next shareholder meeting. while it was probably a good move to refi when the stock was up the funds need to be utilized effectively.

    communication is still very iffy. on a recent trip to san diego i tried to arrange a meeting on sitel i was told that shareholders are not permitted on site, that i should make my comments at the shareholder meeting, i was also told that craig audet would telephone me and i could express my concerns. that never happened.

    so i have three issues, insider confidence, management and communication. i have 200,000 shares to i have not given up. unless these issues are taken seriously by shareholders, our belief in the science may sustain, but our investment will be diluted to nothing.

  • streetmartianx streetmartianx Jan 22, 2015 2:26 PM Flag

    so what is new. arna insiders have never bought a single share on the market. arna is an atm to employees and directors. they don't buy and have no discipline in spending. only with luck will they survive beyond their current cash.

  • streetmartianx by streetmartianx Jan 15, 2015 12:40 PM Flag

    Long term holders of this stock know that this stock has great potential and remain committed. This is with the knowledge that this is a favorite of traders and shorts. We will see the same pattern as before, the stock will be driven down, maybe to the low fours, and then will rise again. The time period for this pattern is now longer,but the forces that existed before haven't gone anywhere. The recent good news from the belphen studies and smoking cessation had no affect on the stock. Recent news coincided with the shorts relaxing and letting it rise. Now they are taking advantage of this upswing and will work it down. When we stop hearing from AF we will know that the shorts have found a better stock for manipulation. Until that time only a dramatic upturn in scripts will propel this stock up. imo

  • Reply to

    Reason for Drop

    by streetmartianx Jan 12, 2015 10:35 PM
    streetmartianx streetmartianx Jan 12, 2015 11:03 PM Flag

    i am holding 17000 shares of this stock so i am not interested in being negative. i am only reporting on the message i received from Navallier this Friday evening in his January report. My view is that if the stock is driven down further, it is a buying opportunity provided that the only issue is production.

    Insider selling is demoralizing but often the people selling are putting kids through college, etc and need the money for expenses. they know the shareholders will continue to give them more options so they live for the moment. they aren't investors, they are employees who have a get it now mentality like all americans. it is not likely that they don't believe in the stock. they just want their money to pay bills.

  • streetmartianx by streetmartianx Jan 12, 2015 10:35 PM Flag

    One of the leading news letters Navallier said to sell because analysts are revising their earnings estimates which means that there will be an earnings miss. given this development and the problem with the fda he recommends selling.

4.6116+0.0616(+1.35%)10:27 AMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.